Security
Aptevo Therapeutics Inc. Common Stock · APVO
APVONASDAQCommon stockCurrentCIK 1671584Updated Nov 13, 2026
APVO price & chart
Loading TradingView…
NASDAQ:APVO on TradingView ↗About the company
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trial, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
424B5 filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders
Items 1.01, 3.03, 9.01
Other Events
Items 8.01, 9.01
S-8 filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 26,996,000Source | 15,146,000Source | 14,519,000Source | 15,624,000Source | 14,921,000Source | 19,902,000Source | 8,342,000Source | 17,629,000Source | 27,194,000Source | 15,591,000Source | 24,842,000Source | 34,215,000Source |
| Property, Plant and Equipment, NetUSD | 384,000Source | 614,000Source | 236,000Source | 432,000Source | 697,000Source | 268,000Source | 482,000Source | 789,000Source | 303,000Source | 543,000Source | 895,000Source | 1,462,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,061,000Source | 7,753,000Source | 9,797,000Source | 9,410,000Source | 8,066,000Source | 14,525,000Source | 2,139,000Source | 10,250,000Source | 21,619,000Source | 8,714,000Source | 16,904,000Source | 22,635,000Source |
| Assets, CurrentUSD | 22,649,000Source | 10,012,000Source | 10,798,000Source | 11,081,000Source | 9,579,000Source | 15,984,000Source | 3,607,000Source | 12,074,000Source | 23,081,000Source | 10,659,000Source | 19,066,000Source | 27,450,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 1,001,000Source | — | — | 1,459,000Source | — | — | 1,462,000Source | — | — | — |
| Operating Lease, Right-of-Use AssetUSD | 3,963,000Source | 4,520,000Source | 3,484,000Source | 4,111,000Source | 4,645,000Source | 3,650,000Source | 4,253,000Source | 4,766,000Source | 3,810,000Source | 4,389,000Source | 4,881,000Source | 5,303,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 9,604,000Source | 10,726,000Source | 8,478,000Source | 9,100,000Source | 10,458,000Source | 8,290,000Source | 9,815,000Source | 11,526,000Source | 9,813,000Source | 10,836,000Source | 12,621,000Source | 16,241,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 110,000Source | 82,000Source | 114,000Source | 99,000Source | 69,000Source | 114,000Source | 84,000Source | 66,000Source | 114,000Source | 84,000Source | 61,000Source | 48,000Source |
| Retained Earnings (Accumulated Deficit)USD | -269,217,000Source | -241,265,000Source | -288,264,000Source | -260,189,000Source | -236,164,000Source | -281,909,000Source | -253,985,000Source | -230,281,000Source | -275,115,000Source | -247,577,000Source | -223,447,000Source | -206,036,000Source |
| Stockholders' Equity Attributable to ParentUSD | 17,392,000Source | 4,420,000Source | 6,041,000Source | 6,524,000Source | 4,463,000Source | 11,612,000Source | -1,473,000Source | 6,103,000Source | 17,381,000Source | 4,755,000Source | 12,221,000Source | 17,974,000Source |
| Additional Paid in Capital, Common StockUSD | 286,499,000Source | 245,603,000Source | 294,191,000Source | 266,614,000Source | 240,558,000Source | 293,407,000Source | 252,428,000Source | 236,318,000Source | 292,382,000Source | 252,248,000Source | 235,607,000Source | 223,962,000Source |
| Liabilities and EquityUSD | 26,996,000Source | 15,146,000Source | 14,519,000Source | 15,624,000Source | 14,921,000Source | 19,902,000Source | 8,342,000Source | 17,629,000Source | 27,194,000Source | 15,591,000Source | 24,842,000Source | 34,215,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,614,000Source | 5,882,000Source | 5,188,000Source | 4,891,000Source | 5,419,000Source | 4,760,000Source | 5,393,000Source | 6,298,000Source | 6,050,000Source | 6,207,000Source | 7,224,000Source | 8,706,000Source |
| Operating Lease, Liability, CurrentUSD | 800,000Source | 700,000Source | 919,000Source | 800,000Source | 700,000Source | 892,000Source | 800,000Source | 700,000Source | 866,000Source | 800,000Source | 700,000Source | 400,000Source |
| Accounts Payable, CurrentUSD | — | — | 1,162,000Source | — | — | 890,000Source | — | — | 877,000Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 3,990,000Source | 4,800,000Source | 3,290,000Source | 4,200,000Source | 5,000,000Source | 3,530,000Source | 4,400,000Source | 5,200,000Source | 3,763,000Source | 4,629,000Source | 5,397,000Source | 6,079,000Source |
| Other Liabilities, NoncurrentUSD | — | 14,000Source | — | — | 14,000Source | — | — | 14,000Source | — | 0Source | — | — |
| Additional Financial Items | ||||||||||||
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,456,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 2,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,456,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -17,411,000Source | 8,027,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 35,000Source | 61,000Source | 240,000Source | 352,000Source | 567,000Source | 901,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 57,000Source | 180,000Source | 96,000Source | 1,069,000Source | 2,193,000Source | 1,802,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,965,000Source | -6,575,000Source | -25,592,000Source | -23,785,000Source | -11,730,000Source | -21,022,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | -29,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 29,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 871,000Source | 0Source | 38,497,000Source | 15,595,000Source | 5,998,000Source | -2,616,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,467,000Source | 12,267,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -7,094,000Source | -6,575,000Source | 12,905,000Source | -8,190,000Source | -5,732,000Source | -23,667,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | — | 22,635,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 100,000Source | 200,000Source | 96,000Source | 1,069,000Source | 2,193,000Source | 1,802,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 200,000Source | 400,000Source | 600,000Source | 900,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | 9,650,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | -47,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 37,182,000Source |
| General and Administrative ExpenseUSD | — | — | 3,566,000Source | 2,110,000Source | 2,747,000Source | 2,898,000Source | 2,913,000Source | 2,847,000Source | 11,772,000Source | 10,224,000Source | 11,771,000Source | 13,873,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,239,000Source | 1,013,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,549,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -17,411,000Source | 8,027,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,028,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,794,000Source | -6,408,000Source | -27,538,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 61,000Source | 112,000Source | 87,000Source | 22,000Source | 140,000Source | 72,000Source | 345,000Source | 472,000Source | 578,000Source | -4,027,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 5,800,000Source | — | — | 872,000Source | 0Source | 37,940,000Source | 10,036,000Source | — | 6,934,000Source |
| Increase (Decrease) in Accounts Payable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 3,114,000Source |
| Operating Income (Loss)USD | — | — | -7,610,000Source | -5,213,000Source | -6,443,000Source | -6,226,000Source | -6,837,000Source | -6,480,000Source | -26,312,000Source | -24,602,000Source | -28,878,000Source | -28,641,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 61,000Source | 112,000Source | 87,000Source | 22,000Source | 140,000Source | 72,000Source | 345,000Source | 472,000Source | 578,000Source | -4,027,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,549,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -17,411,000Source | 8,027,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -5.31Source | -151.29Source | -6.41Source | -1,581.81Source | -87.27Source | -87.38Source | -1.42Source | 1.57Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -5.31Source | -151.29Source | -6.41Source | -1,581.81Source | -87.27Source | -87.38Source | -1.42Source | 1.57Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 1,196,364Source | 41,008Source | 1,060,678Source | 4,051Source | 315,535Source | 276,137Source | 12,234,661Source | 5,100,310Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 1,196,364Source | 41,008Source | 1,060,678Source | 4,051Source | 315,535Source | 276,137Source | 12,234,661Source | 5,102,914Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,566,000Source | 2,110,000Source | 2,747,000Source | 2,898,000Source | 2,913,000Source | 2,847,000Source | 11,772,000Source | 10,224,000Source | 11,771,000Source | 13,873,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.48Source | — | — | — | — | — | -87.38Source | -1.52Source | 1.37Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.48Source | — | — | — | — | — | -87.38Source | -1.52Source | 1.37Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,239,000Source | 1,013,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,028,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,794,000Source | -6,408,000Source | -27,538,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 4,044,000Source | 3,103,000Source | 3,696,000Source | 3,328,000Source | 3,924,000Source | 3,633,000Source | 14,540,000Source | 14,378,000Source | 17,107,000Source | 17,882,000Source |
Offerings
Registration 333-298483
- Offering price
- market-price
- Ticker
- APVO
Registration 333-293010
- Offering amount
- $25,000
- Offering price
- market-price
- Ticker
- APVO
Registration 333-290663
- Offering amount
- $25,000
- Offering price
- market-price
- Ticker
- APVO
Registration 333-288959
- Offering amount
- $25,000
- Offering price
- market-price
- Ticker
- APVO
Registration 333-288061
- Gross proceeds
- 8011250.0
- Net proceeds
- 7450463.0
- Deal price
- 3.25
- Shares
- 2465000
- Offering price
- $3.25
- Ticker
- APVO
Registration 333-287244
Registration 333-284969
- Gross proceeds
- 50000000.0
- Offering amount
- $50,000,000
- Offering price
- at-the-market
- Ticker
- APVO
Registration 333-285476
Filing attachments
apvo-ex4_1.htm · 8-K · 2026-11-12
Exhibit 4.1 THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds SEATTLE, WASHINGTON - November 11, 2026 - Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuan…
Read attachment ↗apvo-ex99_2.htm · 8-K · 2026-11-12
Exhibit 99.2 Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds SEATTLE, WASHINGTON - November 12, 2026 - Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the “Existing Warrants”), pursuant…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumors Preclinical work also showed that APVO711 both activated immune cells and blocked a signal that weakens their response - showing potential to help the immune system fight solid tumors in two wa…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML Refined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further strengthening mipletamig's readiness for Phase 2 development Substantial reduction in infusion reaction frequency and severity improves the patient treatment experience without compromising planned therapeutic dosing Achie…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-10-26
Exhibit 99.1 Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplant Transplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence supporting mipletamig's potential to improve outcomes in frontline AML Aptevo expects the RAINIER dose optimization trial to concl…
Read attachment ↗